

1. Sales January to September 2007 and 2006

	2007	2006	% change	
	CHF m	CHF m	In CHF	In local currencies
January – September				
Pharmaceuticals Division	27,124	23,912	+13	+14
Roche Pharmaceuticals	16,792	14,921	+13	+10
Genentech	7,850	6,522	+20	+24
Chugai	2,482	2,469	+1	+7
Diagnostics Division	6,823	6,415	+6	+5
Roche Group	33,947	30,327	+12	+12

2. Sales January to September 2007 and 2006 excluding Pandemic Tamiflu*

	2007	2006	% change	
	CHF m	CHF m	In CHF	In local currencies
January – September				
Pharmaceuticals Division	25,726	22,678	+13	+14
Roche Pharmaceuticals	15,668	13,816	+13	+11
Genentech	7,850	6,522	+20	+24
Chugai	2,208	2,340	-6	0
Diagnostics Division	6,823	6,415	+6	+5
Roche Group	32,549	29,093	+12	+12

* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

3. Quarterly local sales growth by Division in 2006 and 2007

	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006
Pharmaceuticals Division	+22	+20	+16	+6
Roche Pharmaceuticals	+20	+18	+13	+1
Genentech	+37	+30	+26	+18
Chugai	+2	+11	+2	+8
Diagnostics Division	+5	+6	+5	+4
Roche Group	+18	+17	+13	+6

4. Quarterly local sales growth by Division in 2006 and 2007 excluding Pandemic Tamiflu*

	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006
Pharmaceuticals Division	+16	+16	+14	+12
Roche Pharmaceuticals	+14	+13	+11	+10
Genentech	+37	+30	+26	+18
Chugai	-11	-7	+4	+4
Diagnostics Division	+5	+6	+5	+4
Roche Group	+14	+14	+12	+10

* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

5. Quarterly sales by Division in 2006 and 2007

CHF millions	Q3 2006	Q4 2006	Q1 2007	Q2 2007	Q3 2007
Pharmaceuticals Division	8,335	9,382	9,142	9,126	8,856
Roche Pharmaceuticals	5,251	5,745	5,702	5,665	5,425
Genentech	2,299	2,603	2,547	2,680	2,623
Chugai	785	1,034	893	781	808
Diagnostics Division	2,143	2,332	2,216	2,343	2,264
Roche Group	10,478	11,714	11,358	11,469	11,120

6. Quarterly sales by Division in 2006 and 2007 excluding Pandemic Tamiflu*

CHF millions	Q3 2006	Q4 2006	Q1 2007	Q2 2007	Q3 2007
Pharmaceuticals Division	7,743	8,483	8,396	8,666	8,664
Roche Pharmaceuticals	4,717	4,979	5,151	5,203	5,314
Genentech	2,299	2,603	2,547	2,680	2,623
Chugai	727	901	698	783	727
Diagnostics Division	2,143	2,332	2,216	2,343	2,264
Roche Group	9,886	10,815	10,612	11,009	10,928

* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

7. Top 20 Pharmaceuticals Division product sales¹ and local growth² in YTD September 2007: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	4,084	17%	2,142	13%	135	4%	1,807	23%
Herceptin	3,591	26%	1,170	5%	120	16%	2,301	42%
Avastin	2,971	41%	2,064	35%	13	-	894	58%
NeoRecormon/Epogin	1,584	-4%	-	-	412	-10%	1,172	-2%
Tamiflu	1,573	-2%	564	-8%	325	47%	684	-12%
CellCept	1,464	8%	699	7%	25	16%	740	9%
Pegasys	1,190	10%	286	-9%	42	-4%	862	19%
Xeloda	839	18%	312	19%	20	7%	507	17%
Tarceva	774	34%	371	3%	-	-	403	90%
Lucentis	763	284%	763	284%	-	-	-	-
Bonviva/Boniva	604	97%	405	56%	-	-	199	380%
Xenical	490	-8%	67	-21%	-	-	423	-6%
Xolair	429	13%	429	13%	-	-	-	-
Valcyte/Cymevene	398	14%	195	10%	-	-	203	18%
Nutropin	357	2%	347	2%	-	-	10	-1%
Pulmozyme	355	11%	200	12%	-	-	155	9%
Kytril	315	-15%	106	-30%	99	7%	110	-14%
Rocephin	299	-4%	18	-19%	42	7%	239	-4%
Neutrogen	295	13%	-	-	295	13%	-	-
Activase/TNKase	294	14%	262	16%	-	-	32	-3%

¹ Roche Pharmaceuticals, Genentech and Chugai combined ² versus YTD September 2006

8. Top 20 Pharmaceuticals Division quarterly local product sales growth¹ in 2006 and 2007

	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006
MabThera/Rituxan	17%	17%	16%	17%
Herceptin	58%	36%	25%	18%
Avastin	49%	41%	39%	45%
NeoRecormon/Epogin	-1%	-3%	-5%	-5%
Tamiflu	43%	47%	25%	-60%
CellCept	7%	7%	14%	4%
Pegasys	6%	15%	7%	7%
Xeloda	16%	14%	18%	20%
Tarceva	71%	44%	31%	28%
Lucentis	-	-	1964%	31%
Bonviva/Boniva	251%	132%	123%	62%
Xenical	6%	-10%	-6%	-9%
Xolair	23%	16%	13%	11%
Valcyte/Cymevene	30%	15%	19%	9%
Nutropin	8%	5%	-2%	3%
Pulmozyme	11%	4%	15%	14%
Kytril	-10%	-16%	-18%	-11%
Rocephin	-32%	-7%	-2%	-2%
Neutrogen	7%	11%	12%	15%
Activase/TNKase	14%	15%	20%	6%

¹ Roche Pharmaceuticals, Genentech and Chugai combined

9. Pharmaceuticals Division quarterly local product sales growth¹ US in 2006 and 2007

	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006
MabThera/Rituxan	15%	13%	12%	14%
Herceptin	29%	7%	3%	6%
Avastin	36%	34%	33%	37%
NeoRecormon/Epogin	-	-	-	-
Tamiflu	33%	-8%	196%	-71%
CellCept	13%	3%	18%	-1%
Pegasys	-6%	6%	-5%	-27%
Xeloda	16%	2%	23%	30%
Tarceva	27%	9%	-1%	1%
Lucentis	-	-	1964%	31%
Bonviva/Boniva	205%	83%	77%	27%
Xenical	11%	-24%	-8%	-30%
Xolair	23%	16%	13%	11%
Valcyte/Cymevene	38%	8%	20%	4%
Nutropin	8%	5%	-2%	3%
Pulmozyme	8%	6%	17%	14%
Kytril	-26%	-28%	-36%	-28%
Rocephin	-94%	-34%	-7%	-13%
Neutrogen	-	-	-	-
Activase/TNKase	11%	18%	24%	6%

¹ Roche Pharmaceuticals and Genentech combined

10. Pharmaceuticals Division quarterly local product sales growth Japan¹ in 2006 and 2007

	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006
MabThera/Rituxan	1%	1%	6%	4%
Herceptin	26%	23%	25%	3%
Avastin	-	-	-	-
NeoRecormon/Epogin	-12%	-17%	-3%	-12%
Tamiflu	36%	55%	-93%	48%
CellCept	14%	21%	14%	14%
Pegasys	-37%	-38%	-5%	34%
Xeloda	-9%	3%	6%	11%
Tarceva	-	-	-	-
Lucentis	-	-	-	-
Bonviva/Boniva	-	-	-	-
Xenical	-	-	-	-
Xolair	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Nutropin	-	-	-	-
Pulmozyme	-	-	-	-
Kytril	5%	7%	5%	8%
Rocephin	4%	4%	5%	11%
Neutrogen	7%	11%	12%	15%
Activase/TNKase	-	-	-	-

¹ Chugai

11. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World¹ in 2006 and 2007

	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006
MabThera/Rituxan	22%	23%	21%	23%
Herceptin	87%	61%	43%	26%
Avastin	101%	63%	52%	59%
NeoRecormon/Epogin	5%	3%	-6%	-2%
Tamiflu	52%	76%	-48%	-70%
CellCept	0%	10%	10%	9%
Pegasys	19%	23%	13%	22%
Xeloda	17%	22%	16%	15%
Tarceva	211%	125%	94%	68%
Lucentis	-	-	-	-
Bonviva/Boniva	885%	658%	400%	278%
Xenical	5%	-7%	-6%	-5%
Xolair	-	-	-	-
Valcyte/Cymevene	21%	21%	17%	15%
Nutropin	14%	0%	4%	-7%
Pulmozyme	16%	1%	13%	14%
Kytril	-5%	-15%	-19%	-4%
Rocephin	-10%	-5%	-2%	-4%
Neutrogen	-	-	-	-
Activase/TNKase	31%	-6%	-4%	1%

¹ Roche Pharmaceuticals

12. Top Pharmaceuticals Division quarterly product sales¹ in 2006 and 2007

CHF millions	Q3 2006	Q4 2006	Q1 2007	Q2 2007	Q3 2007
MabThera/Rituxan	1,177	1,314	1,309	1,395	1,380
Herceptin	1,009	1,105	1,168	1,214	1,209
Avastin	741	832	923	986	1,062
NeoRecormon/Epogin	535	592	522	544	518
Tamiflu	669	997	865	451	257
CellCept	466	485	476	503	485
Pegasys	350	393	400	407	383
Xeloda	239	260	267	282	290
Tarceva	211	235	243	260	271
Lucentis	192	273	263	261	239
Bonviva/Boniva	142	179	170	204	230
Xenical	160	170	163	176	151
Xolair	135	145	136	148	145
Valcyte/Cymevene	126	139	124	137	137
Nutropin	118	132	117	122	118
Pulmozyme	108	116	111	120	124
Kytril	127	117	105	100	110
Rocephin	96	104	100	104	95
Neutrogen	91	100	96	99	100
Activase/TNKase	89	95	96	106	92

¹ Roche Pharmaceuticals, Genentech and Chugai combined

13. Pharmaceuticals Division quarterly product sales¹ in US in 2006 and 2007

CHF millions	Q3 2006	Q4 2006	Q1 2007	Q2 2007	Q3 2007
MabThera/Rituxan	650	737	682	742	718
Herceptin	374	398	383	403	384
Avastin	539	606	657	689	718
NeoRecormon/Epogin	-	-	-	-	-
Tamiflu	361	275	147	319	98
CellCept	241	264	217	250	232
Pegasys	107	122	104	107	75
Xeloda	90	111	89	109	114
Tarceva	123	132	125	125	121
Lucentis	192	273	263	261	239
Bonviva/Boniva	122	144	120	135	150
Xenical	25	27	24	26	17
Xolair	135	145	136	148	145
Valcyte/Cymevene	68	77	56	70	69
Nutropin	115	127	114	118	115
Pulmozyme	62	66	65	67	68
Kytril	56	39	39	27	40
Rocephin	6	2	6	7	5
Neutrogen	-	-	-	-	-
Activase/TNKase	78	81	88	94	80

¹ Roche Pharmaceuticals and Genentech combined

14. Pharmaceuticals Division quarterly product sales¹ in Japan in 2006 and 2007

CHF millions	Q3 2006	Q4 2006	Q1 2007	Q2 2007	Q3 2007
MabThera/Rituxan	49	56	38	48	49
Herceptin	40	46	36	45	39
Avastin	-	-	-	3	10
NeoRecormon/Epogin	147	194	124	164	124
Tamiflu	57	173	246	-2	81
CellCept	8	9	7	9	9
Pegasys	14	15	10	15	17
Xeloda	7	7	6	7	7
Tarceva	-	-	-	-	-
Lucentis	-	-	-	-	-
Bonviva/Boniva	-	-	-	-	-
Xenical	-	-	-	-	-
Xolair	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Nutropin	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Kytril	34	40	29	35	35
Rocephin	13	17	12	16	14
Neutrogen	91	100	96	99	100
Activase/TNKase	-	-	-	-	-

¹ Chugai

15. Pharmaceuticals Division quarterly product sales in Europe/Rest of World¹ in 2006 and 2007

CHF millions	Q3 2006	Q4 2006	Q1 2007	Q2 2007	Q3 2007
MabThera/Rituxan	478	521	589	605	613
Herceptin	595	661	749	766	786
Avastin	202	226	266	294	334
NeoRecormon/Epogin	388	398	398	380	394
Tamiflu	251	549	472	134	78
CellCept	217	212	252	244	244
Pegasys	229	256	286	285	291
Xeloda	142	142	172	166	169
Tarceva	88	103	118	135	150
Lucentis	-	-	-	-	-
Bonviva/Boniva	20	35	50	69	80
Xenical	135	143	139	150	134
Xolair	-	-	-	-	0
Valcyte/Cymevene	58	62	68	67	68
Nutropin	3	5	3	4	3
Pulmozyme	46	50	46	53	56
Kytril	37	38	37	38	35
Rocephin	77	85	82	81	76
Neutrogen	-	-	-	-	-
Activase/TNKase	11	14	8	12	12

¹ Roche Pharmaceuticals